

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

FOR IMMEDIATE RELEASE

24 November 2008

Recommended Acquisition

by

HCL EAS Limited
an indirect wholly owned subsidiary of

HCL Technologies Limited

of

Axon Group plc

Results of Court Meeting and General Meeting

Axon Group plc ("**Axon**" or the "**Company**") announces that, the meeting convened by the Court and held earlier today (the "**Court Meeting**") and at the subsequent extraordinary general meeting ("**General Meeting**") to approve the scheme of arrangement (the "**HCL Scheme**") to implement the acquisition of the Company by HCL EAS Limited (the "**HCL Acquisition**") were concluded successfully.

Vineet Nayar, CEO and Member of the Board, HCL Technologies commenting on the vote said "We are very pleased that the Axon shareholders have approved HCL's offer for the company. This acquisition continues to make sound strategic sense for HCL especially in the current macro economic situation.

"Axon has achieved a significant degree of success in creating a leading SAP implementation services business which when combined with HCL's enterprise applications services, offshore capabilities and complementary market presence in North America, Europe and Asia will help drive the ongoing expansion of product and service capabilities in the global IT Services sector.

In addition this acquisition provides HCL with scale, significant revenue synergies and exposure to Axon's considerable client base where the majority of revenues are generated from defensive sectors including the UK public sector."

The Court Meeting

At the Court Meeting, a majority in number of the Scheme Shareholders who voted, either in person or by proxy, representing over 75 per cent. in value of all of the Scheme Shares voted, voted in favour of the HCL Scheme and, accordingly, the resolution was passed.

The General Meeting

At the General Meeting, the special resolution proposed to approve the HCL Scheme and the associated HCL Reduction of Capital was passed as a special resolution on a show of hands.

Completion of the HCL Acquisition remains subject to the satisfaction or, if appropriate, waiver of the HCL Conditions set out in the scheme document sent to Axon Shareholders on 24 October 2008 (the "**Scheme Document**"), including, amongst other things, the sanction of both the HCL Scheme and the associated HCL Reduction of Capital by the Court.

A request will be made to each of the London Stock Exchange and the UKLA prior to the HCL Effective Date to cancel the trading in Axon Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Axon Shares from the Official List, in each case, with effect from the HCL Effective Date or shortly thereafter.

It should be noted that the last day of dealings in, and for registration of transfers of, and disablement in CREST of, Axon Shares will be 4.30 p.m. on the business day following the HCL Scheme Hearing (which is expected to be 10 December 2008) following which Axon Shares will be temporarily suspended from the Official List and the London Stock Exchange's main market for listed securities.

It is expected that the HCL Effective Date will be 15 December 2008.

A detailed timetable of events for the HCL Scheme is set out in the Scheme Document. These dates are indicative only and will depend, amongst other things, on the date on which the Court sanctions the HCL Scheme and the associated HCL Reduction of Capital. If the expected dates change, the Company will give notice of the changes in an announcement through a Regulatory Information Service.

Copies of the Scheme Document are available for inspection during normal business hours on any business day at the offices of Osborne Clarke at One London Wall, London EC2Y 5EB, up to and including the HCL Effective Date.

Words and expressions defined in the Scheme Document shall, unless the context provides otherwise, have the same meanings in this announcement.

Enquiries:

Axon

Stephen Cardell
Iain McIntosh
Roy Merritt

Tel: +44 (0)1784 480 800

Citi (financial adviser and joint corporate broker to Axon)

William Barter
Richard Moore
Charles Lytle

Tel: +44 (0)20 7986 6946

Tel: +44 (0)20 7986 5376

Tel: +44 (0)20 7986 0519

Panmure Gordon (joint corporate broker to Axon)

Dominic Morley

Tel: +44 (0)20 7614 8388

Bell Pottinger (PR adviser to Axon)

Chris Hamilton

Tel: +44 (0)7870 257 276

Mike Davis

Tel: +44 (0)7871 255 055

HCL Technologies

Sandip Gupta

Tel: +91 12 0438 1095

Ram Krishna

Merrill Lynch (Financial adviser to HCL)

Kevin J. Smith

Tel: +44 (0)20 628 1000

Mohsin Rashid

Raphael Grunschlag

Andrew Fairclough (Corporate Broking)

Standard Chartered (Financial adviser to HCL)

Amer Baig

Tel: +44 (0)20 7885 8888

Thomas Pfeiffer

Maitland (PR adviser to HCL)

Philip Gawith

Tel: +44 (0)20 7379 5151

Liz Morley

Citi, which is authorised and regulated in the United Kingdom by the FSA, is acting exclusively for Axon and no one else in connection with the HCL Acquisition and will not be responsible to anyone other than Axon for providing the protections afforded to clients of Citi nor for providing advice in relation to the HCL Acquisition, the content of this announcement or any matter referred to herein.

Merrill Lynch, which is authorised and regulated in the United Kingdom by the FSA, is acting exclusively for HCL Technologies and HCL EAS and no one else in connection with the HCL Acquisition and will not be responsible to anyone other than HCL Technologies and HCL EAS for providing the protections afforded to clients of Merrill Lynch nor for providing advice in relation to the HCL Acquisition, the content of this announcement or any matter referred to herein.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, 'interested' (directly or indirectly) in one per cent. or more of any class of 'relevant securities' of Axon, all 'dealings' in any 'relevant securities' of Axon (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30 p.m. (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the Acquisition becomes effective, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of Axon, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the City Code, all 'dealings' in 'relevant securities' of Axon by HCL Technologies or HCL EAS, or Axon, or by any of their respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to the application of Rule 8 to you, please contact an independent financial adviser authorised under the

Financial Services and Markets Act 2000, consult the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on telephone number +44 (0) 20 7382 9026; fax +44 (0) 20 7638 1554.